Results 71 to 80 of about 311,418 (261)

Description of adverse reactions reported in the pharmacovigilance database of province of Las Tunas

Revista Electrónica Dr. Zoilo E. Marinello Vidaurreta, 2017
Background: adverse drug effects are a health problem on a worldwide scale and increase the costs of hospital care considerably.Objective: to describe the adverse drug reactions reported to the pharmacovigilance database of the province of Las Tunas ...
Sahily Rojas-Pérez, Maité Rúa-Del-Toro, Yaneicy Laguna-Reyes, Daiosmy Espinosa-Palacio, Eslhey María Sánchez-Domínguez   +4 more
doaj  

Drug-induced oral ulcerations: case report

Acta Clinica Croatica, 2016
A 70-year-old patient was admitted to the Department of Oral Medicine for multiple oral ulcerations on the left buccal mucosa, around 0.5 cm in diameter, as well as on the gingiva.
Vanja Vučičević Boras, Snježana Židovec-Lepej, Branka Marinović, Sven Seiwerth, Ivana Škrinjar, Dražen Pulanić, Danica Vidović Juras   +6 more
doaj   +1 more source

Risk factors associated with adverse reactions to antituberculosis drugs [PDF]

Jornal Brasileiro de Pneumologia, 2015
This review sought to identify the available scientific evidence on risk factors associated with adverse reactions to antituberculosis drugs. We performed a systematic review of studies published in the 1965-2012 period and indexed in the MEDLINE and ...
Laíse Soares Oliveira Resende, Edson Theodoro dos Santos-Neto   +1 more
doaj   +4 more sources

Assessing the 2004-2018 fentanyl misusing issues reported to an international range of adverse reporting systems [PDF]

, 2019
© 2019 Schifano, Chiappini, Corkery and Guirguis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).
Chiappini, Stephania, Corkery, John, Guirguis, Amira, Schifano, Fabrizio   +3 more
core   +4 more sources

Applying an Ethical Lens to the Treatment of People With Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The practice of neurology requires an understanding of clinical ethics for decision‐making. In multiple sclerosis (MS) care, there are a wide range of ethical considerations that may arise. These involve shared decision‐making around selection of a disease‐modifying therapy (DMT), risks and benefits of well‐studied medications in comparison to
Methma Udawatta, Farrah J. Mateen
wiley   +1 more source

Pharmacokinetic Herb-Drug Interactions: Insight into Mechanisms and Consequences [PDF]

, 2015
Herbal medicines are currently in high demand, and their popularity is steadily increasing. Because of their perceived effectiveness, fewer side effects and relatively low cost, they are being used for the management of numerous medical conditions ...
Horie, Toshiharu, Oga, Enoche Florence, Sekine, Shuichi, Shitara, Yoshihisa   +3 more
core   +1 more source

Exploring Patients’ Profiles Associated With the Resolution of Acute Calcium Pyrophosphate Arthritis Treated With Colchicine and Prednisone: Post Hoc Analysis of a Randomized Controlled Trial

Arthritis Care &Research, EarlyView.
Objective The objective was to identify factors determining acute arthritis resolution and safety with colchicine and prednisone in acute calcium pyrophosphate (CPP) crystal arthritis. Methods We conducted a post hoc analysis of the COLCHICORT trial, which compared colchicine and prednisone for the treatment of acute CPP crystal arthritis, using a ...
Tristan Pascart, Laurène Norberciak, Pascal Richette, Pierre Robinet, Aurore Pacaud, Gauthier Marchasson, Thibault Rabin, Hélène Luraschi, Pierre Maciejasz, Anne‐France Georgel, Augustin Latourte, Hang‐Korng Ea, Sébastien Ottaviani, Charlotte Jauffret, Vincent Ducoulombier   +14 more
wiley   +1 more source

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network [PDF]

, 2013
Background: Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients.
A Bashey, A Eckert, A Ribas, AA Sarnaik, Armin Justich, AV Maker, AV Maker, Axel Hauschild, Beatrice Schuler-Thurner, C Robert, Carmen Loquai, Carola Berking, Caroline J. Voskens, Caroline Robert, Christina Klein, Christine Mateus, Claus Garbe, Clemens L. Bockmeyer, Daniela Göppner, Dirk Schadendorf, F Bompaire, F Fadel, F Torino, FS Hodi, FS Hodi, G Berthod, G Borodic, G Graziani, G Graziani, G Hunter, G Hunter, Gerold Schuler, Gheorghe Hundorfean, GQ Phan, GY Ku, H Gogas, H Tlaskalova-Hogenova, H. Peter Soyer, HB Wang, Imke Satzger, J Delyon, JA Blansfield, JD Wolchok, JD Wolchok, Jens Ulrich, JJ Nordlund, JM Kirkwood, JS Weber, JS Weber, JS Weber, Julia Vaubel, K Harmankaya, K Sanderson, Katharina C. Kaehler, KD Chmiel, KE Beck, L Min, LM Heinzerling, Lucie M. Heinzerling, Marc Schlaeppi, Michael Fluck, OP Hamnvik, P Attia, PA Prieto, Patrik Weder, Peter Mohr, Ralf Gutzmer, Reinhard Dummer, RH Friedline, Roger von Moos, Rüdiger Hein, S Bhatia, S Wilgenhof, S Wilgenhof, S Wilgenhof, SG Downey, Simone M. Goldinger, SM Liu, Stephan Grabbe, Sylvie Paetzold, T Bakacs, T Matsui, Tabea Wilhelm, Tanja Bergmann, Thomas Eigentler, Ullrich Keller, Uwe Trefzer, WB Breunis, WV Vogel   +88 more
core   +4 more sources

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, Accepted Article.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; NCT04179032) used three‐weight‐band ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) network investigators   +14 more
wiley   +1 more source

Sex differences in medication discontinuation in axial spondyloarthritis.

Arthritis Care &Research, Accepted Article.
Objective We examined sex differences in medication discontinuation among patients with axial spondyloarthritis (axSpA) initiating tumor necrosis factor inhibitors (TNFi), interleukin‐17 inhibitors (IL‐17i), or Janus kinase inhibitors (JAKi). Methods Using data from the Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), we ...
Rachael Stovall, Cinthia Blat, Eric Roberts, Jean W. Liew, Katherine Wysham, Namrata Singh, Janna Friedly, Lianne S. Gensler, Gabriela Schmajuk, Jinoos Yazdany   +9 more
wiley   +1 more source